How The Midwest Was Won: Creating A New Epicenter For Device Innovation And Investment

Talent, innovation, world-class research institutions, established supply chains, and a lower cost of doing business – what else do you need to launch and grow a device company? Well, capital, for one. Players in the Midwest are working in a variety of ways to draw entrepreneurs and venture money to the region, and their efforts are reaping positive results.

The American Midwest brings to mind images of vast, fertile fields of wheat, corn, and other important crops, but its significance is now much more than agricultural. The often unassuming US heartland – comprising Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin – is also a fast-growing hotbed for medical device research and development, entrepreneurship, and investment. With industry-leading manufacturers such as Medtronic PLC, St. Jude Medical Inc., Hologic Inc., GE Healthcare/General Electric Co., Cook Group Inc., Boston Scientific Corp., 3M Co., DePuy Orthopaedics Inc./Johnson & Johnson, Biomet Inc., and Zimmer Biomet Holdings Inc. headquartered in the Midwest, the region has long been known for developing and manufacturing a wide variety of advanced implantable devices and imaging technologies. In fact, DePuy, Biomet, and Zimmer alone comprise one-third of the world's orthopedics industry, according to Indiana life sciences accelerator BioCrossroads. And, with its established outsourcing and supply chains, world-class research universities, including Case Western Reserve University and the University of Wisconsin, Madison, a large talent pool, and lower cost of doing business, the Midwest is turning out to be fertile soil indeed for device entrepreneurs launching a new venture.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

OneCell Diagnostics – Now 1Cell.Ai - Launches Multi-Modal Cancer Diagnostic Panel OncoIncytes

 

OneCell Diagnostics, the Mumbai-based startup backed with $16m in series A funding, is rebranding to 1Cell.Ai to represent the firm's focus on combining deep science with AI-powered capabilities.

Makary Proposes Combined Adverse Event Reporting Systems In Megyn Kelly Interview

 

In discussing FDA’s adverse event monitoring, Makary also seemed to falsely imply the agency did not fully investigate the myocarditis signal with COVID-19 vaccines.

Upcoming CMS Meetings Address Tremor-Control Devices, Lab Test Reimbursement

 
• By 

The US Medicare agency will hold three public meetings in June and July addressing tremor treatment devices and clinical diagnostic lab tests. The first meeting on June 25 will focus on endpoints for Parkinson’s device trials, while subsequent meetings will address payment rates and codes for laboratory tests.

Trump’s Preliminary 2026 HHS Budget Plan Protects US FDA User Fee Collection

 
• By 

The preliminary White House 2026 budget plan cuts agency funding, but not so sharply that user fees are excluded from collection.

More from North America

Congress, Researchers Highlight Security Risks At DNA Testing Services

 
• By 

Congress has launched an inquiry into 23andMe amid privacy concerns following its bankruptcy, particularly regarding the potential sale of sensitive user data. Additionally, a Cybernews report gave 40 DNA testing firms an average cybersecurity grade of D, citing widespread vulnerabilities and data breaches, along with inadequate public information about their security practices.

Looking Back Towards The Future

 

As it celebrates 75 years shaping the medtech industry, Medtronic invited Medtech Insight to its Minneapolis headquarters to get a closer look at the company’s past, what it’s working on now, and what’s on the horizon.

Guidance Feedback Highlights Outstanding Questions In AI Development

 
• By 

Many of the hundred-plus commenters to the FDA's draft guidance on AI in medical product regulation said the document was a good start but needed additional clarity and more concrete examples. Stakeholders recommended the inclusion of case studies, metrics, and clearer guidelines to enhance the utility of the guidance, which is seen as a vital step for AI integration in healthcare.